Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. In addition, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics for an offering of germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

Myriad Genetics, Inc.

Myriad Genetics focuses on advancing health through genetic testing, providing insights for hereditary cancer risk assessment, prenatal care, cancer management, and mental health treatment. The company self-describes its role in precision medicine.

Myriad Genetics

Myriad UroSuite™

Personalized Medicine & Companion Diagnostics

Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. 

RainDance Technologies

Whether a woman has a personal or family history of cancer, genetic testing may help them uncover information that can help guide medical management decisions if they are at higher risk for cancer. Melissa Gonzales, President of Women's Health at Myriad, authored this Healthcare Business Today article on three genetic testing trends advancing women’s health in 2024. 

Here's a sneak peek:
📈 Bridging The Awareness Gap About Family Health History 
📈 New Research, Evolving Guidelines Drive Push For Genetic Testing
📈 Genetic Testing Fears Declining

Learn more: https://lnkd.in/gVESf_pK 

#genetictesting #womenshealth 

Join us for our January webinar in our Evolving Strategies in Genetics and Genomics 2024 continuing education webinar series. Our January webinar will highlight recent literature related to universal and germline testing in oncology genetics as well as unexpected findings in reproductive genetic screening with Alexandra Lisi and Flora Days.
 
Registration links are below: 
Tuesday, January 23rd, 2024 at 12:00PM ET
Registration Link: https://lnkd.in/esNM6uqz
Thursday, January 25th, 2024 at 3:00PM ET
Registration Link: https://lnkd.in/e87hzgPc
 
**This event has been approved by the National Society of Genetic Counselors (NSGC)  for Category 1 CEUs. The American Board of Genetic Counseling (ABGC) accepts CEUs approved by NSGC for purposes of recertification.  
  
**This nursing continuing professional development activity is pending approval for 1.25 contact hours from Oregon Nurses Association (ONA), an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation (ANCC).  Contact hours will be awarded to participants who attend the presentation and complete the post-activity survey. 
 
We look forward to having you join us this week! 


#continuingeducation #nurses #nursingeducation #geneticcounselor

Please join Myriad Genetics for our January webinar in our Evolving Strategies in Genetics and Genomics 2024 continuing education webinar series. Our January webinar will highlight recent literature related to universal and germline testing in oncology genetics as well as unexpected findings in reproductive genetic screening with Alexandra Lisi and Flora Days.
 
Registration links are below: 
Tuesday, January 23rd, 2024 at 12:00PM ET
Registration Link: https://lnkd.in/esNM6uqz
Thursday, January 25th, 2024 at 3:00PM ET
Registration Link: https://lnkd.in/e87hzgPc
 
**This event has been approved by the National Society of Genetic Counselors (NSGC)  for Category 1 CEUs. The American Board of Genetic Counseling (ABGC) accepts CEUs approved by NSGC for purposes of recertification.  
  
**This nursing continuing professional development activity is pending approval for 1.25 contact hours from Oregon Nurses Association (ONA), an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation (ANCC).  Contact hours will be awarded to participants who attend the presentation and complete the post-activity survey. 
 
We look forward to having you join us this week! 


#continuingeducation #nurses #nursingeducation #geneticcounselor
 

We're excited to announce that we have entered into a definitive agreement to acquire select assets from Intermountain Precision Genomics’ (IPG) laboratory business, including the Precise™ Tumor Test, the Precise Liquid Test, and IPG’s CLIA-certified laboratory in St. George, Utah where the Precise Tumor Test is currently performed. Learn more: https://lnkd.in/edYjC4_V

“With this acquisition, we’re deepening our commitment to our oncology business while also generating a more effective way to scale and grow our tumor profiling and liquid biopsy tests, including operational efficiencies, reimbursement benefits and new clinical development opportunities,” said Paul Diaz, president and CEO, Myriad Genetics. “We’d like to thank our longstanding partners at Intermountain Health for the important progress they’ve made in advancing precision oncology care. We look forward to continuing to build on this foundation to provide comprehensive genomic profiling options to the Intermountain Health System and its patients and providers that can help guide clinical care and improve patient outcomes.”

#oncology #genetictesting

What a year 2023 was - promoted to senior rep, team MVP & another President’s Club win. 

NSM in Tampa last week was great, loved getting to see so many friends and colleagues and to plan for a great 2024! ✨Grateful to work for Myriad Genetics and with my incredible manager & Mighty Mid team 🧬I love the work I’m able to do everyday - to directly impact the lives of many women (and men) through the testing Myriad provides. Here’s to 2024!

Service is love in action. It has the power to bring communities together, help others stand together against hate, build bridges, and heal divides. Service unites people regardless of race, ability, religion, or zip code. Now is the time to act on Dr. King’s “fierce urgency of now” and deliver on the promise of a Beloved Community. 

Remember, no act of kindness is too small. How are you serving your community today?

#MLKDay #BelovedCommunity #IServed

NASDAQ:MYGN

Myriad Genetics

Last Close

26.55

25/09 14:38

Market Cap

2.28B

Beta: 1.64

Volume Today

61.77K

Avg: 616.92K

PE Ratio

−6.54

PFCF: −13.02

locale

market

industry

website

ipo date

Earnings

Earnings per Share (Estimate*)

Revenue (Estimate*)

Metrics